A significant portion of the anti-tumour response induced by DMXAA was lost in IFNAR-deficient mice and Batf3−/− mice, supporting the role of cDC1s and type I IFN signalling in STING agonist activity [155]. This evidence concerns the gene STING1 and neoplasm.